Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MapLight Therapeutics, Inc.MPLT · Entity 5316 | Director | June 23, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MapLight Therapeutics, Inc.
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | Direct | 28,932 |
Reported balance
After 2026-06-23 transaction · row 1
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 3,932 · Balance 28,932 F1: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. F2: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.64 · Expires 2036-06-22 | Direct | 14,902 |
Reported balance
After 2026-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-23 · Grant · Acquired 14,902 · Balance 14,902 F3: Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.
F2: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
F3: Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 25, 2026 21:54 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantStock Option (right to buy) · Derivative | 14,902 | $0.00 Strike: $28.64 | $0.00 |
DisclosureSEC source: 0001470798-26-000004 · form4-06252026_090639.xml · derivative · entry 2 Pavlov George · CIK 0001470798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,902 Underlying: Voting Common Stock · 14,902 shares Expires 2036-06-22 F3 · derivative.exercise_date: Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 21:54 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantVoting Common Stock | 3,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001470798-26-000004 · form4-06252026_090639.xml · nonDerivative · entry 1 Pavlov George · CIK 0001470798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,932 F1 · shares: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
| February 20, 2026 Filed Feb 20, 2026 23:25 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | PurchaseVoting Common Stock | 9,920 | $17.86 | $177,171.20 |
DisclosureSEC source: 0001470798-26-000002 · form4-02202026_060201.xml · nonDerivative · entry 3 Pavlov George · CIK 0001470798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.74 to $17.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 23:25 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | PurchaseVoting Common Stock | 4,422 | $17.57 | $77,694.54 |
DisclosureSEC source: 0001470798-26-000002 · form4-02202026_060201.xml · nonDerivative · entry 2 Pavlov George · CIK 0001470798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,080 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.28 to $17.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:25 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | PurchaseVoting Common Stock | 10,658 | $17.48 | $186,301.84 |
DisclosureSEC source: 0001470798-26-000002 · form4-02202026_060201.xml · nonDerivative · entry 1 Pavlov George · CIK 0001470798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,658 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.22 to $17.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.